This website is best viewed in a browser that supports web standards.
Skip to content or, if you would rather, Skip to navigation.
Aug. 21, 2024Elwood, Kan. | By: Jeremy Werner
ELWOOD, Kan. - Elanco Animal Health is expanding its biologics manufacturing facility in Elwood, Kansas, with a 25,000-square-foot addition.
The $130 million investment is expected to be completed by 2026. It will support growth in monoclonal antibody technology, which is crucial for new animal health innovations.
This facility currently manufactures a targeted treatment for canine parvovirus, a disease that affects hundreds of thousands of puppies annually.
The expansion will double production capacity and include a pilot plant, quality control lab, and support spaces.
Elanco’s leaders emphasized the importance of advancing technologies that enhance pet care as part of the company’s research and development strategy.
The Elwood facility will play a key role in producing new products, including a potential canine dermatology treatment in 2025. The project is led by design-build firm Burns and McDonnell in Kansas City.